A New York based startup is facing intense scrutiny after launching a controversial subway advertising campaign promoting “genetically optimized” IVF. Nucleus Genomics is offering prospective parents the option to genetically screen embryos for $8,999, claiming its technology can predict a wide range of traits, including disease risks, intelligence, ADHD, autism, height, and more. The company says it uses full DNA sequencing combined with polygenic scoring to provide parents with detailed predictions about their future child.
While Nucleus Genomics presents the technology as a groundbreaking advancement in reproductive choice, experts have cautioned that the science behind predicting complex traits remains highly unreliable. Critics have also condemned the campaign, describing it as a modern form of eugenics repackaged as a consumer product. Despite these ethical and scientific concerns, the startup has reported a dramatic 1,700% increase in sales following the launch of its marketing campaign, even though no successful embryo selections using this technology have been confirmed.
The campaign has reignited debates over the ethics of genetic selection, the potential social consequences of “designer babies,” and the limitations of current genetic science. As reproductive technology continues to advance, Nucleus Genomics’ bold marketing has made it a focal point for discussions about the future of human reproduction.
